海圣医疗过会：今年IPO过关第71家 中信证券过8单

Core Viewpoint - Zhejiang Haisheng Medical Devices Co., Ltd. has passed the IPO review by the Beijing Stock Exchange, marking it as the 71st company to receive approval this year, with a total of 28 companies approved by the Beijing Stock Exchange [1] Company Overview - Haisheng Medical is a global provider of anesthesia and monitoring medical devices, focusing on the research, production, and sales of these products, which are widely used in various clinical departments such as anesthesia, ICU, and emergency [2] - The controlling shareholders of Haisheng Medical are Huang Haisheng and Wu Xiaoye, who together control 54.92% of the company's shares [2] IPO Details - Haisheng Medical plans to publicly issue up to 11,294,118 shares, or up to 12,988,235 shares if the overallotment option is fully exercised, ensuring that public shareholders hold at least 25% of the total share capital post-issue [3] - The company aims to raise approximately 370.43 million yuan, which will be allocated to upgrading and expanding production of anesthesia and monitoring emergency medical devices, establishing a research and testing center, and building a marketing service base [3] Review Meeting Inquiries - The review meeting raised inquiries regarding the authenticity and accuracy of financial information, the impact of industry policies such as volume-based procurement and the "two-invoice system" on the company's operational stability, and the progress of research and development for active devices [4]